Showing results (111-120 of 172) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|January 21, 2009
Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesionY Hou, B J Rabquer, M L Gerber, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
Arthritis and Rheumatism|February 14, 2012
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisP A Merkel, N P Silliman, P J Clements, et al.
Arthritis and Rheumatism|May 28, 2011
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo GroupDinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain modelE W Ehrich, A Dallob, I De Lepeleire, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|May 3, 2007
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseReda E Girgis, Adaani E Frost, Nicholas S Hill, et al.
Pageof 18